Duloxetine ['Cymbalta'], a serotonin/norepinephrine inhibitor (SNRI), is well tolerated and effective in the treatment of depression, according to studies presented at the 155th Annual Meeting of the American Psychiatric Association (APA) [Philadelphia, US; May 2002].*Results from several phase III studies demonstrated the superiority of duloxetine, administered once or twice daily, over placebo. Furthermore, duloxetine proved more effective than the selective serotonin reuptake inhibitor (SSRI), paroxetine, in one of these studies. Data from pooled studies demonstrated that duloxetine has a favourable tolerability profile, with minimal effects on bodyweight, cardiovascular abnormalities and sexual function.